首页 | 本学科首页   官方微博 | 高级检索  
     

针对新冠肺炎的放射性治疗药物研究
引用本文:罗志福,樊彩云,李凤林,陈宝军,刘子华,解清华.针对新冠肺炎的放射性治疗药物研究[J].同位素,2022,35(1):67-69.
作者姓名:罗志福  樊彩云  李凤林  陈宝军  刘子华  解清华
作者单位:中国原子能科学研究院,北京102413
基金项目:中国原子能科学研究院的资金支持
摘    要:基于核技术在现代医学中有十分广泛的应用,本工作提出用放射性药物治疗新型冠状病毒肺炎或其他冠状病毒引发疾病的颠覆性创新思路.围绕该思路进行了可行性分析、理论计算和实验工作,完成了目标药物分子的设计和制备;进行了其与新冠病毒刺突蛋白受体结合域(RBD)的亲和力以及和新冠病毒假病毒粒子的结合评价;进行了放射性药物分子的制备、...

关 键 词:新冠肺炎  放射性治疗药物  冠状病毒

Radiopharmaceuticals for the Treatment of COVID-19
LUO Zhifu,FAN Caiyun,LI Fenglin,CHEN Baojun,LIU Zihua,XIE Qinghua.Radiopharmaceuticals for the Treatment of COVID-19[J].Isotopes,2022,35(1):67-69.
Authors:LUO Zhifu  FAN Caiyun  LI Fenglin  CHEN Baojun  LIU Zihua  XIE Qinghua
Affiliation:China Institute of Atomic Energy, Beijing 102413, China
Abstract:Based on the wide application of nuclear technology in modern medicine, this work proposes a breakthrough idea for the treatment of COVID-19 or diseases induced by other coronavirus with radiopharmaceuticals. The analysis of feasibility, theoretical calculation and experimental works were carried out around this idea, and the design and preparation of the target molecules were completed. Its affinity with SARS-CoV-2 spike protein binding domain (RBD) and its binding with SARS-CoV-2 false virus particles were evaluated. The preparation of radiopharmaceutical molecules, biological distribution in normal mice and acute toxicity experiments were carried out. The effectiveness and safety of the radiopharmaceuticals in the treatment of COVID-19 will be evaluated in further work, which maybe a new nuclear technology for dealing with major infectious diseases.
Keywords:COVID-19  therapeutic radiopharmaceuticals  treatment  coronavirus
本文献已被 维普 等数据库收录!
点击此处可从《同位素》浏览原始摘要信息
点击此处可从《同位素》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号